Plan complexity and robustness are two essential aspects of treatment plan quality but there is a great variability in their management in clinical practice. This study reports the results of the 2020 ESTRO survey on plan complexity and robustness to identify needs and guide future discussions and consensus. A survey was distributed online to ESTRO members. Plan complexity was defined as the modulation of machine parameters and increased uncertainty in dose calculation and delivery. Robustness was defined as a dose distribution's sensitivity towards errors stemming from treatment uncertainties, patient setup, or anatomical changes. A total of 126 radiotherapy centres from 33 countries participated, 95 of them (75%) from Europe and Central Asia. The majority controlled and evaluated plan complexity using monitor units (56 centres) and aperture shapes (38 centres). To control robustness, 98 (97% of question responses) photon and 5 (50%) proton centres used PTV margins for plan optimization while 75 (94%) and 5 (50%), respectively, used margins for plan evaluation. Seventeen (21%) photon and 8 (80%) proton centres used robust optimisation, while 10 (13%) and 8 (80%), respectively, used robust evaluation. Primary uncertainties considered were patient setup (photons and protons) and range calculation uncertainties (protons). Participants expressed the need for improved commercial tools to control and evaluate plan complexity and robustness. Clinical implementation of methods to control and evaluate plan complexity and robustness is very heterogeneous. Better tools are needed to manage complexity and robustness in treatment planning systems. International guidelines may promote harmonization.
New treatment modalities in radiotherapy (RT) enable delivery of highly conformal dose distributions in patients. This creates a need for precise dose verification in three dimensions (3D). A radiochromic silicone-based 3D dosimetry system has recently been developed. Such a dosimeter can be used for dose verification in deformed geometries, which requires knowledge of the dosimeter’s mechanical properties. In this study we have characterized the dosimeter’s elastic behaviour under tensile and compressive stress. In addition, the dose response under strain was determined. It was found that the dosimeter behaved as an incompressible hyperelastic material with a non-linear stress/strain curve and with no observable hysteresis or plastic deformation even at high strains. The volume was found to be constant within a 2% margin at deformations up to 60%. Furthermore, it was observed that the dosimeter returned to its original geometry within a 2% margin when irradiated under stress, and that the change in optical density per centimeter was constant regardless of the strain during irradiation. In conclusion, we have shown that this radiochromic silicone-based dosimeter’s mechanical properties make it a viable candidate for dose verification in deformable 3D geometries.
1 July 2018 in Physics and Imaging in Radiation Oncology
The limited image quality in Cone Beam CT (CBCT) stemming primarily from scattered radiation hinders accurate CBCT based dose calculation in radiotherapy. We investigated the use of a stoichiometric calibration for dose calculation on CBCT images of lung cancer patients. CBCT calibrations were performed with thorax scan protocols, using a phantom with approximately the diameter of an average human thorax and a central cavity simulating the thoracic cavity. Thus scatter conditions resembling those in clinical thorax CBCT scans were simulated. A published stoichiometric parametrization was used. A treatment plan was simulated on CBCT and CT scans of an anthropomorphic phantom, the dose distributions were calculated, and clinically relevant DVH parameters were compared. Twelve lung cancer patients had surveillance CT scans (s-CT) taken twice during their treatment course in addition to daily setup CBCTs. Dose calculations were performed on the s-CTs and the corresponding CBCTs taken on the same day, and DVH parameters were compared. Eighty percent of CBCT DVH parameters found for the phantom were within ±1% of CT doses, and 98% were within ±3%. For patients, the median CT/CBCT dose difference was within ±2%, and 98% of DVH parameters were within ±4%. Minimum dose to the tumor was underestimated (median 1.9%) on CBCT, while maximum doses to most organs at risk were slightly overestimated. Direct dose calculations on CBCTs of lung cancer patients were feasible within ∼4% accuracy using a simple calibration method, which is easily implemented in a clinical setting.
Background and purpose: Reirradiation is becoming more frequent in clinical practice. However, workflows and practices vary widely between clinics, as general guidelines are scarce or lacking in practical detail. This paper presents comprehensive national Danish consensus recommendations covering all steps of the reirradiation workflow. The aim is to standardise and improve reirradiation treatment quality and provide guidance for much-needed large-scale clinical trials. Methods: An expert panel was formed comprising physicians, clinical physicists, and clinical researchers from all Danish radiotherapy centres. An in-person 2-day workshop was followed by multiple online meetings. Recommendations were based on expert consensus, supported by review of existing literature, and were reviewed by all Danish Multidisciplinary Cancer Groups before publication. Results: Reirradiation cases should be designated clearly as such at each workflow step. Review of patient cases at multidisciplinary reirradiation conferences is encouraged. Immobilisation, positioning, and motion management should resemble that of previous treatment(s) as closely as possible. Information on previous dose should be used in planning and evaluation. The degree of complexity (e.g. summation of dose maxima, rigid/deformable image registration, 3D dose accumulation) should reflect the clinical situation as well as the extent/quality of available information. Dose should always be converted to an equieffective dose before summation. Daily image-guidance and regular evaluation of delivered dose are recommended. We provide guidance on quality assurance of dose mapping and guidelines for clinical reirradiation trials. Interpretation: We present national consensus guidelines for site-independent reirradiation treatment workflows. The guidelines have been approved by the site-specific Danish Multidisciplinary Cancer Groups.
Background and purpose: Reirradiation has seen increased interest and clinical use; however, robust data on patient numbers and treatment indications are missing. As a precursor to a prospective national reirradiation registry, a comprehensive national audit of reirradiation was performed. Patients/materials and methods: Radiotherapy retreatment courses in 2023 were audited by all (eight) radiotherapy centres in Denmark. Six centres extended the evaluation to include 2021–22, and three of these also evaluated preceding years. Reirradiation was defined according to the ESTRO/EORTC consensus (i.e. treatment volume overlap or cumulative dose toxicity risk) using 3 months threshold between the primary and reirradiation courses. Reirradiation courses were further stratified into curative/ablative and palliative treatments by prescription dose. Results: The total number of radiotherapy patients at Danish centres in 2023 was 17,424. Of these, 3,163 received retreatment, including 1,471 reirradiation courses (1,035 palliative; 436 curative/ablative). From 2014 to 2023, absolute numbers for both retreatment and reirradiation increased. We found large variation in prescription doses and fractionation schedules used for reirradiation. Widely used palliative prescriptions were 8Gy/1 fraction (F), 20Gy/4F and 30Gy/10F; stereotactic prescriptions of 20Gy/1F or 27Gy/3F in brain and 45Gy/3F in lung; and a variety of curative treatments schedules. Palliative reirradiations were primarily thoracic (29%), spine (25%), and abdominal/pelvic (22%) and curative/ablative reirradiations were primarily breast (29%) and lung stereotactic (23%). Interpretation: This is the first comprehensive national audit of reirradiation, demonstrating an increasing number of patients being treated, using a wide variety of dose prescriptions and fractionation schedules.
High-dose lung cancer reirradiation is promising but associated with high toxicity risk. Development of and adherence to consensus guidelines will support safe use. Literature review and live workshops were conducted to develop treatment planning guidelines in preparation for the Scandinavian CURE Lung trial. Relevant OARs, dose metrics, constraints, and priorities were considered. For six high-dose reirradiation lung cancer cases, the physical 3D dose distribution of previous treatment was mapped to current CT. The cases were distributed to eight radiotherapy centres, which optimised plans on current CT respecting equieffective cumulative dose constraints. Mapped previous dose and current dose were rescaled to EQD2Gy (α/β = 3 Gy, spinal cord: α/β = 2 Gy), summed by each centre, and reviewed centrally. After cases 1-4 were completed, prioritisation between OAR constraints and target coverage was clarified. Consensus agreement on guidelines for treatment planning, equieffective cumulative dose constraints, and priorities was established. For cases 1-3, centres complied with constraints. For case 4, covering PTV while respecting OAR constraints was difficult, and major variations were identified, underscoring the need for clearer prioritisation guidance. Consensus was reached to prioritise OAR constraints, and centres re-optimised case 4 accordingly. For cases 5 and 6, all centres underdosed PTV, to comply with OAR constraints. Generally, considerable variation in cumulative OAR doses was observed. A treatment planning protocol was developed. The pre-trial multi-centre treatment planning study identified and resolved key missing guidance to facilitate common conception of consensus guidelines. Feasibility and compliance with the proposed equieffective cumulative dose constraints were established.